283 related articles for article (PubMed ID: 25471178)
1. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Massey PR; Okman JS; Wilkerson J; Cowen EW
Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
3. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
5. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
7. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
8. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
Ding F; Liu B; Wang Y
J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
[TBL] [Abstract][Full Text] [Related]
9. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
10. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
12. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
13. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
15. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
16. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.
Hasan Alshammari A; Masuo Y; Fujita KI; Shimada K; Iida N; Wakayama T; Kato Y
Biochem Pharmacol; 2022 Mar; 197():114914. PubMed ID: 35041812
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
18. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Li J; Gu J
Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
[TBL] [Abstract][Full Text] [Related]
19. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]